Correction: Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy

J Exp Clin Cancer Res. 2023 May 30;42(1):135. doi: 10.1186/s13046-023-02703-3.

Authors

Chrysostomi Gialeli^{1

2}, Emre Can Tuysuz¹, Johan Staaf³, Safa Guleed¹, Veronika Paciorek¹, Matthias Mörgelin⁴, Konstantinos S Papadakos¹, Anna M Blom⁵

Affiliations

¹ Department of Translational Medicine, Lund University, Malmö, Sweden.
² Experimental Cardiovascular Research Group, Department of Clinical Sciences, Lund University, Malmö, Sweden.
³ Division of Oncology, Department of Clinical Sciences Lund, Lund University, Medicon Village, Lund, Sweden.
⁴ Colzyx AB, Lund, Sweden.
⁵ Department of Translational Medicine, Lund University, Malmö, Sweden. anna.blom@med.lu.se.

No abstract available

Publication types

Published Erratum